Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans.
about
Propranolol blocks cardiac and neuronal voltage-gated sodium channelsAntianginal actions of beta-adrenoceptor antagonistsAntihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approachesOxandrolone Coadministration Does Not Alter Plasma Propranolol Concentrations in Severely Burned Pediatric Patients.Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat.Epidemiology and management of antiretroviral-associated cardiovascular disease.A general mechanism for drug promiscuity: Studies with amiodarone and other antiarrhythmicsOphthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems.BCL::EMAS--enantioselective molecular asymmetry descriptor for 3D-QSAR.Impact of Antihypertensive Treatment on Maternal and Perinatal Outcomes in Pregnancy Complicated by Chronic Hypertension: A Systematic Review and Meta-Analysis.Cyclodextrine screening for the chiral separation of carvedilol by capillary electrophoresis.Monitoring the effects of chiral pharmaceuticals on aquatic microorganisms by metabolic fingerprinting.Pharmacokinetic-pharmacodynamic modelling of S(-)-atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint.Design, Development and Optimization of S (-) Atenolol Floating Sustained Release Matrix Tablets Using Surface Response MethodologyWhole body physiologically based modelling of beta-blockers in the rat: Events in tissues and plasma following an intravenous bolus dose.In vivo evaluation of antimyotonic efficacy of β-adrenergic drugs in a rat model of myotonia.Melittin stimulates fatty acid release through non-phospholipase-mediated mechanisms and interacts with the dopamine transporter and other membrane-spanning proteins.Chirality and drugs used to treat psychiatric disorders.Revisiting atenolol as a low passive permeability marker.Development of a New Method Based on Chiral Ligand-Exchange Chromatography for the Enantioseparation of Propranolol.Partial Agonist and Biased Signaling Properties of the Synthetic Enantiomers J113863/UCB35625 at Chemokine Receptors CCR2 and CCR5.Small bowel obstruction in the elderly: a plea for comprehensive acute geriatric careLinking Aromatic Hydroxy Metabolic Functionalization of Drug Molecules to Structure and Pharmacologic Activity
P2860
Q21129289-3E2A9184-209E-4E6F-8BB9-93F08E0821C4Q24682302-3156EF0E-C5C8-40EE-A44C-865B51F353F4Q26861570-60113E66-3744-4CED-B093-5877CFF60D07Q30490969-438589AA-F690-48DA-AD0C-B31CBD858435Q35003086-FC9FAFE8-BE29-4731-B325-F6F3572CE291Q35338096-5F5DF3E9-18E1-400F-82D6-3D58770B3F42Q36333201-643BEBD4-6C03-427E-85DF-8B0D9710B52BQ36440361-4F97EE35-823A-43AE-A8DD-185E320D9AA8Q38423627-3BC5F341-AF28-4790-8DCE-CFEB5035DA70Q38780214-FB331256-1BE8-48F5-B51C-CE5E7DF6EB53Q39785592-9A65919D-7E8A-44DD-82C9-3F9AA28B2E36Q39892404-26EC1E04-9BC9-4182-8173-89444A88C4A7Q41587356-8FB5DB32-EE7D-494E-9DB2-6D2861628E60Q41888180-C02EEB80-9320-4817-93DB-B11476C1D301Q42698035-001BE2B4-B880-4664-A4E5-FED9E7457403Q42742246-9E1DDAFE-4AFD-4D9D-A2C0-DC705D1349EDQ42777714-CAEFC382-AD59-4E35-AAE4-5F4AEBFDB202Q42875648-69D2035F-7C2B-4D87-A831-FDB96BF504A6Q43214475-4AA2E829-8436-47AC-AFB0-B88DA1E1BCC3Q45431810-BD283914-E3A3-446B-AE8A-366F465C63E5Q48193375-E67A1E32-4CAF-411A-B0E3-D3AFD10FE962Q58120726-A6756078-C999-46B9-8B4D-686EB2EF97D6Q58691462-0F6EEFDD-A4D9-4B59-B089-E77EE7CB4684
P2860
Stereospecific pharmacokinetics and pharmacodynamics of beta-adrenergic blockers in humans.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Stereospecific pharmacokinetic ...... adrenergic blockers in humans.
@ast
Stereospecific pharmacokinetic ...... adrenergic blockers in humans.
@en
Stereospecific pharmacokinetic ...... adrenergic blockers in humans.
@nl
type
label
Stereospecific pharmacokinetic ...... adrenergic blockers in humans.
@ast
Stereospecific pharmacokinetic ...... adrenergic blockers in humans.
@en
Stereospecific pharmacokinetic ...... adrenergic blockers in humans.
@nl
prefLabel
Stereospecific pharmacokinetic ...... adrenergic blockers in humans.
@ast
Stereospecific pharmacokinetic ...... adrenergic blockers in humans.
@en
Stereospecific pharmacokinetic ...... adrenergic blockers in humans.
@nl
P1476
Stereospecific pharmacokinetic ...... adrenergic blockers in humans.
@en
P2093
P304
P407
P577
2001-05-01T00:00:00Z